A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Tuberculosis is the leading cause of death in AIDS patients, yet the current tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), is contraindicated for immunocompromised individuals, including human immunodeficiency virus-positive persons, because it can cause disseminated disease; moreover, its efficacy is suboptimal. To address these problems, we have engineered BCG mutants that grow normally in vitro in the presence of a supplement, are preloadable with supplement to allow limited growth in vivo, and express the highly immunoprotective Mycobacterium tuberculosis 30-kDa major secretory protein. The limited replication in vivo renders these vaccines safer than BCG in SCID mice yet is sufficient to induce potent cell-mediated and protective immunity in the outbred guinea pig model of pulmonary tuberculosis. In the case of one vaccine, rBCG( mbtB )30, protection was superior to that with BCG (0.3-log fewer CFU of M. tuberculosis in the lung [ P < 0.04] and 0.6-log fewer CFU in the spleen [ P = 0.001] in aerosol-challenged animals [means for three experiments]); hence, rBCG( mbtB )30 is the first live mycobacterial vaccine that is both more attenuated than BCG in the SCID mouse and more potent than BCG in the guinea pig. Our study demonstrates the feasibility of developing safer and more potent vaccines against tuberculosis. The novel approach of engineering a replication-limited vaccine expressing a recombinant immunoprotective antigen and preloading it with a required nutrient, such as iron, that is capable of being stored should be generally applicable to other live vaccine vectors targeting intracellular pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trunz, B. B., Fine, P., & Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68507-3 · Cited by 1,114 · cited 1×
“The tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), one of the most widely used human vaccines, is administered to approximately 100 million infants annually (49).”
BackgroundGenome plasticity of BCG and impact on vaccine efficacy
Brosch, R., Gordon, S. V., Garnier, T., Eiglmeier, K., Frigui, W., Valenti, P., Dos Santos, S., Duthoy, S., Lacroix, C., Garcia-Pelayo, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700869104 · Cited by 574
De Voss, J. J., Rutter, K., Schroeder, B. G., Su, H., Zhu, Y., & Barry, C. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1252 · Cited by 532 · cited 4×
“tuberculosis H37Rv mbtB mutant, which was reported to grow normally in iron-replete broth without added mycobactin (10).”
BackgroundInfluentialSmith, D. A., Parish, T., Stoker, N. G., & Bancroft, G. J. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.1442-1150.2001 · Cited by 243
Sambandamurthy, V. K., Derrick, S. C., Hsu, T., Chen, B., Larsen, M. H., Jalapathy, K. V., Chen, M., Kim, J., Porcelli, S. A., Chan, J., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.097 · Cited by 213
Sampson, S. L., Dascher, C. C., Sambandamurthy, V. K., Russell, R. G., Jacobs, W. R., Bloom, B. R., & Hondalus, M. K. (2004) · Infection and Immunity · doi:10.1128/iai.72.5.3031-3037.2004 · Cited by 153 · cited 1×
“tuberculosis leucine and pantothenate double auxotroph provided protection comparable to that of BCG (5, 29, 46).”
BackgroundSambandamurthy, V. K., Derrick, S. C., Jalapathy, K. V., Chen, B., Russell, R. G., Morris, S. L., & Jacobs, W. R. (2005) · Infection and Immunity · doi:10.1128/iai.73.2.1196-1203.2005 · Cited by 138
Cited by
Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
Ottenhoff, T. H. M., & Kaufmann, S. H. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002607 · Cited by 455
Kaufmann, S. H., Hussey, G., & Lambert, P.-H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60393-5 · Cited by 299
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence
Tufariello, J. M., Chapman, J. R., Kerantzas, C. A., Wong, K.-W., Vilchèze, C., Jones, C. M., Cole, L. E., Tinaztepe, E., Thompson, V., Fenyö, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523321113 · Cited by 215
Discovery and characterization of a unique mycobacterial heme acquisition system
Tullius, M. V., Harmston, C. A., Owens, C. P., Chim, N., Morse, R. P., McMath, L. M., Iniguez, A., Kimmey, J. M., Sawaya, M. R., Whitelegge, J. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009516108 · Cited by 199
“A recombinant bacillus Calmette-Guérin (rBCG) mutant with an interrupted mycobactin/exomycobactin biosynthetic pathway surprisingly multiplied, albeit at a rate considerably less than the parental strain, in SCID mice (7).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Tullius, M. V., Harth, G., Masleša-Galić, S., Dillon, B. J., & Horwitz, M. A.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2008-11
- Volume
- 76
- Issue
- 11
- Pages
- 5200-5214
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2150710643
- Cited by
- 82
- References
- 7
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.